Mirum Pharmaceuticals, Inc. MIRM
Regular-session close
After hours · Nov 20, 4:51 PM ET
- YTD
- +21.70%
- 1 year
- +39.00%
5D +3.10 (+3.35%)
- Market cap
- 6.28B
- Revenue (ttm)
- 670.78M
- Profit margin
- -134.75%
- EPS (ttm)
- -14.47
- Shares out
- 65.28M
- Forward P/E
- 300.41
- YTD return
- +21.70%
- 1-year return
- +39.00%
- 50-day average
- 88.23
- 200-day average
- 98.18
- Volume
- 1.06M
- Avg volume
- 687.35K
- Open
- 94.50
- Previous close
- 95.51
- Day's range
- 94.10 – 98.39
- 52-week range
- 63.23 – 130.00
- Beta
- 0.74
- Analysts
- Strong Buy
- Price target
- 157.71 (+64.1%)
- Earnings date
- Feb 24, 2027
Key statistics
- Enterprise value
- 6.60B
- Price / sales
- 9.36
- Revenue growth
- 39.60%
- Free cash flow
- 98.39M
- Total cash
- 373.69M
- Total debt
- 743.56M
- Return on equity
- -760.01%
- Short % of float
- 12.84%
Fundamental scorecard
3 of 25 checks passed on MIRM’s reported financials
3of 25 checks passed
- Value 0 of 5
- Growth 1 of 5
- Profitability 1 of 5
- Financial health 1 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Analyst view
Consensus: strong buy
- Target (low)
- 118.00
- Target (mean)
- 157.71
- Target (high)
- 202.28
- Strong buy4
- Buy8
- Hold0
- Sell0
- Strong sell0
Next earnings
Feb 24, 2027
Expected Feb 24, 2027. Consensus EPS estimate -0.56.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 24, 2027 | Dec 30, 2026 | -0.67 | — | — | — |
| Nov 3, 2026 | Sep 30, 2026 | -0.48682 | -0.87 | -0.38 | -78.71% |
| Aug 5, 2026 | Jun 30, 2026 | -0.74254 | -1.06 | -0.32 | -42.75% |
| May 6, 2026 | Mar 31, 2026 | -0.40 | -13.43 | -13.03 | -3,257.50% |
| Feb 25, 2026 | Dec 31, 2025 | 0.02 | -0.11 | -0.13 | -650.00% |
| Nov 4, 2025 | Sep 30, 2025 | -0.10 | 0.05 | +0.15 | +150.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 11, 2026 | Citigroup | main | Buy | Buy |
| Nov 5, 2026 | Leerink Partners | main | Outperform | Outperform |
| Nov 4, 2026 | RBC Capital | reit | Outperform | Outperform |
| Nov 4, 2026 | Citizens | main | Market Outperform | Market Outperform |
| Nov 4, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Nov 4, 2026 | Cantor Fitzgerald | main | Overweight | Overweight |
About Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases; Brelovitug, for the treatment of chronic HDV infection, which is in Phase 2 clinical trial; and MRM-3379, that is in Phase 2 clinical study for the treatment of FXS. The company has a collaboration agreement with the Shire International GmbH; License Agreement with Pfizer Inc.; Sanofi-Aventis Deutschland GmbH; Novartis Pharma AG; Lonza Ltd.; Enthorin Therapeutics, LLC and Dart Neuroscience LLC; Asset Purchase Agreement with Asklepion Pharmaceuticals, LLC; License and Manufacturing Agreement with LGM Pharma; and Asset Purchase Agreement with Travere Therapeutics, Inc. The company was incorporated in 2018 and is headquartered in Foster City, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- mirumpharma.com
News
AMG TimesSquare Small Cap Growth Fund Q3 2026 Portfolio Activity Citigroup Maintains Buy on Mirum Pharmaceuticals, Raises Price Target to $194
Leerink Partners Maintains Outperform on Mirum Pharmaceuticals, Lowers Price Target to $140
CORRECTION: RBC Capital Reiterates Outperform on Mirum Pharmaceuticals, Maintains $155 Price Target
RBC Capital Reiterates Outperform on Mirum Pharmaceuticals, Maintains $155 Price Target
Citizens Maintains Market Outperform on Mirum Pharmaceuticals, Raises Price Target to $167
HC Wainwright & Co. Maintains Buy on Mirum Pharmaceuticals, Raises Price Target to $202
Cantor Fitzgerald Maintains Overweight on Mirum Pharmaceuticals, Raises Price Target to $160
Mirum Pharmaceuticals Q3 2026 Earnings Call Transcript Mirum Pharmaceuticals Raises FY2026 Sales Guidance from $680.000M-$700.000M to $715.000M-$720.000M vs $698.093M Est
Your note
Sign in to keep a note on MIRM — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BJERKHOLT ERIC H | Chief Financial Officer | Sale | Sep 13, 2026 | 44,745 |
| BREGE LAURA A | Director | Conversion of Exercise of derivative security | Sep 10, 2025 | 15,703 |
| FISCHER LAURENT D M.D. | Director | Conversion of Exercise of derivative security | May 28, 2026 | 10,727 |
| GREY MICHAEL G. | Director | Conversion of Exercise of derivative security | Dec 18, 2025 | 280,160 |
| HERON PATRICK J | Director | Purchase | Jan 22, 2026 | 0 |
| HOWE JOLANDA MARIE | Officer | Conversion of Exercise of derivative security | Oct 15, 2026 | 16,728 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 11.76% | 7,679,684 | 738.25M | Sep 29, 2026 |
| Janus Henderson Group Ltd. | 8.48% | 5,537,329 | 532.30M | Sep 29, 2026 |
| Blackrock Inc. | 7.24% | 4,723,295 | 454.05M | Sep 29, 2026 |
| FMR, LLC | 6.24% | 4,073,752 | 391.61M | Sep 29, 2026 |
| Vanguard Portfolio Management LLC | 4.03% | 2,633,578 | 253.17M | Sep 29, 2026 |
| Price (T.Rowe) Associates Inc | 3.90% | 2,544,392 | 244.59M | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.52% | 1,648,210 | 158.44M | Jun 29, 2026 |
| Fidelity Rutland Square TRT II-Strategic Advisers Fidelity U.S. Total | 2.28% | 1,487,523 | 143.00M | Sep 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 1.88% | 1,229,029 | 118.15M | Sep 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 1.88% | 1,228,809 | 118.13M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 1.82% | 1,189,194 | 114.32M | Jun 29, 2026 |
| SmallCap World Fund Inc | 1.72% | 1,123,070 | 107.96M | Sep 29, 2026 |
